NEW YORK (GenomeWeb News) – The Joslin Diabetes Center will use Metabolon’s biochemical profiling technology in human clinical and animal studies of insulin resistance and type 2 diabetes, Metabolon said today.
Research Triangle Park, NC-based Metabolon also will assess the translatability of its human insulin resistance biomarkers when conducting the Joslin diabetic animal model studies. In addition, the partners will collaborate on further validation studies of human biochemical markers of insulin resistance.
Metabolon noted that it is working with academic centers around the world on developing a diagnostic test for insulin resistance, a condition which the firm said affects more than a quarter of the US adult population.
“Mechanism-based biomarker diagnostics are a much-needed tool in the identification and management of patients at risk for type 2 diabetes and cardiovascular disease," Metabolon CEO John Ryals said in a statement. "Our partnership with Joslin gives us the opportunity to further validate the biomarkers of insulin resistance that we have identified."
Financial and other terms of the collaboration were not disclosed.